Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Core Insights - Clearmind Medicine Inc. has successfully completed treatment for all patients in the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The second cohort included six patients from leading clinical sites such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, completing treatment as per protocol [2] - This milestone follows positive results from the first cohort, which indicated a favorable safety profile and preliminary efficacy, including reduced cravings and withdrawal symptoms [2][3] - The CEO of Clearmind Medicine expressed satisfaction with the progress and highlighted the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs [3] Group 2: Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]